| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;111:3119-3125.)
© 2005 American Heart Association, Inc.
Vascular Medicine |
From the Vascular Biology Unit, School of Medicine, James Cook University, Townsville (C.S.M., M.M., M.K., N.K., J.G.), and School of Surgery and Pathology, University of Western Australia, Fremantle (P.N.), Australia.
Correspondence to Associate Professor Jonathan Golledge, School of Medicine, James Cook University, James Cook Drive, Douglas, Townsville, 4811 Australia. E-mail jonathan.golledge{at}jcu.edu.au
Received April 22, 2004; revision received February 6, 2005; accepted February 10, 2005.
Background Abdominal aortic aneurysm (AAA) is characterized by destruction of the arterial media associated with loss of vascular smooth muscle cells, infiltration of mononuclear cells, and high concentration of metalloproteinases (MMPs) and cytokines. Osteoprotegerin (OPG) has recently been identified in atherosclerosis. The presence and functional importance of OPG in human AAA was investigated.
Methods and Results In 146 men with small AAA followed up by ultrasound for 3 years, serum OPG was weakly correlated with aneurysm growth rate. Western analysis showed 3-, 8-, and 12-fold-greater OPG concentrations in human AAA biopsies compared with biopsies of atherosclerotic narrowed aorta (1.4±0.1 versus 0.5±0.1 ng/mg tissue; P=0.002), postmortem nondiseased abdominal aorta (1.4±0.1 versus 0.2±0.1 ng/mg tissue; P<0.001), and nondiseased thoracic aorta (1.4±0.1 versus 0.1±0.06 ng/mg tissue; P<0.001). Healthy human aortic vascular smooth muscle cells incubated with recombinant human (rh)OPG (0 to 20 ng rhOPG/105 cells per 1 mL per 24 hours) developed an aneurysmal phenotype defined by impaired cell proliferation (P<0.001), increased apoptosis (P<0.01), and increased MMP-9 (92 kDa) expression (P<0.001). Incubation of monocytic THP-1 cells with 1 ng rhOPG/105 cells per 1 mL per 24 hours induced a 2-fold increase in MMP-9 expression (P<0.001), a 1.5-fold increase in MMP-2 activity (P=0.005), and a 2-fold stimulation of IL-6 production in these cells (P=0.02). Finally, secretion of OPG from human AAA explant was abrogated by treatment with the angiotensin II blocker irbesartan, with the reduction in secreted levels averaging 63.0±0.9 ng/mg tissue per 48-hour period.
Conclusions These findings support a role for OPG in the growth of human AAA and suggest a potential benefit for angiotensin II blockade in slowing aneurysm expansion.
Key Words: aneurysm apoptosis osteoprotegerin metalloproteinases muscle, smooth
This article has been cited by other articles:
![]() |
J. Golledge, M. Karan, C. S. Moran, J. Muller, P. Clancy, A. E. Dear, and P. E. Norman Reduced expansion rate of abdominal aortic aneurysms in patients with diabetes may be related to aberrant monocyte-matrix interactions Eur. Heart J., March 1, 2008; 29(5): 665 - 672. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Mangan, A. V. Campenhout, C. Rush, and J. Golledge Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-{alpha} associated with induction of angiopoietin-2 Cardiovasc Res, December 1, 2007; 76(3): 494 - 505. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kiechl, G. Schett, J. Schwaiger, K. Seppi, P. Eder, G. Egger, P. Santer, A. Mayr, Q. Xu, and J. Willeit Soluble Receptor Activator of Nuclear Factor-{kappa}B Ligand and Risk for Cardiovascular Disease Circulation, July 24, 2007; 116(4): 385 - 391. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Zauli, F. Corallini, F. Bossi, F. Fischetti, P. Durigutto, C. Celeghini, F. Tedesco, and P. Secchiero Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo Blood, July 15, 2007; 110(2): 536 - 543. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Golledge, S. Mangan, and P. Clancy Effects of Peroxisome Proliferator-Activated Receptor Ligands in Modulating Tissue Factor and Tissue Factor Pathway Inhibitor in Acutely Symptomatic Carotid Atheromas Stroke, May 1, 2007; 38(5): 1501 - 1508. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Secchiero, F. Corallini, A. Pandolfi, A. Consoli, R. Candido, B. Fabris, C. Celeghini, S. Capitani, and G. Zauli An Increased Osteoprotegerin Serum Release Characterizes the Early Onset of Diabetes Mellitus and May Contribute to Endothelial Cell Dysfunction Am. J. Pathol., December 1, 2006; 169(6): 2236 - 2244. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Golledge, J. Muller, A. Daugherty, and P. Norman Abdominal Aortic Aneurysm: Pathogenesis and Implications for Management Arterioscler. Thromb. Vasc. Biol., December 1, 2006; 26(12): 2605 - 2613. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Bennett, M. Scatena, E. A. Kirk, M. Rattazzi, R. M. Varon, M. Averill, S. M. Schwartz, C. M. Giachelli, and M. E. Rosenfeld Osteoprotegerin Inactivation Accelerates Advanced Atherosclerotic Lesion Progression and Calcification in Older ApoE-/- Mice Arterioscler. Thromb. Vasc. Biol., September 1, 2006; 26(9): 2117 - 2124. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. V. Anand, A. Lahiri, E. Lim, D. Hopkins, and R. Corder The Relationship Between Plasma Osteoprotegerin Levels and Coronary Artery Calcification in Uncomplicated Type 2 Diabetic Subjects J. Am. Coll. Cardiol., May 2, 2006; 47(9): 1850 - 1857. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |